Cognitive impairment in elderly patients with rheumatic disease and the effect of disease-modifying anti-rheumatic drugs
- PDF / 425,424 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 31 Downloads / 215 Views
REVIEW ARTICLE
Cognitive impairment in elderly patients with rheumatic disease and the effect of disease-modifying anti-rheumatic drugs Akhil Sood 1
&
Mukaila A. Raji 2
Received: 26 May 2020 / Revised: 17 August 2020 / Accepted: 25 August 2020 # International League of Associations for Rheumatology (ILAR) 2020
Abstract Recent development of biologic disease-modifying anti-rheumatic drugs (DMARDs) has led to better control of disease activity among patients with chronic rheumatological diseases. Many patients with rheumatic disease are living longer, adding to the growing elderly population. Rheumatic diseases, most notably rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), are known to increase the risk of cognitive impairment. Systemic inflammation associated with chronic rheumatological diseases has been postulated to be key driver of cognitive decline. Recent development of classic and biologic DMARDs have led to better control of disease activity among patients with rheumatic conditions. It is proposed that strict control of systemic inflammation will significantly lower the risk of cognitive impairment among patients with rheumatic disease. The impact of classic DMARDs on cognitive function appears to be variable. On the other hand, biologic DMARDs, specifically antitumor necrosis factor (TNF) drugs (i.e., etanercept), have been shown to significantly lower the risk of dementia. Experimental studies on IL-1, IL-6, and B and T cell blockade are promising. However, clinical data is limited. Preclinical studies on targeted therapies, specifically JAK/STAT inhibitors, also show promising results. Additional studies are necessary to better understand the impact of these newer biologic agents on cognitive function in elderly patients with rheumatic disease. Key points • Patients with chronic rheumatic conditions are beginning to live longer, adding to the elderly population. • Patients with chronic rheumatologic disease are at increased risk of cognitive impairment compared to the general population. • Recent development of biologic (i.e., TNF, IL-1, IL-6) and targeted drugs (i.e., Janus kinase inhibitors) have led to better control of disease activity. • Current evidence suggests that TNF inhibitors may have beneficial effects on cognitive function. However, evidence on newer biologic and targeted therapies is limited.
Keywords Aging . Biologics . Cognition . Rheumatic diseases
Introduction Use of disease-modifying anti-rheumatic drugs (DMARDs)— especially the biologics—is rising in the geriatric population.
* Akhil Sood [email protected] Mukaila A. Raji [email protected] 1
Department of Internal Medicine, University of Texas Medical Branch (UTMB), 301 University Blvd, Galveston, TX 77555-0177, USA
2
Division of Geriatrics & Palliative Medicine, Department of Internal Medicine, University of Texas Medical Branch (UTMB), Galveston, TX, USA
Many with rheumatic disease (RD) live longer and are now on DMARDs. Biologic DMARDs (bDMARDs) have substantially improved the quality of life, activities of
Data Loading...
